The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases.
The company's marketed therapies include JAKAFI for blood cancer, ICLUSIG for leukemia, PEMAZYRE for bile-duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also advancing a growing clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.
Broadcom Just Named Its Next AI Customer. It Isn't Google.
Broadcom Just Named Its Next AI Customer. It Isn't Google.
Dear Microsoft Stock Fans, Mark Your Calendars for September 24
Dear Microsoft Stock Fans, Mark Your Calendars for September 24
Why It's Time to Load Up on Micron Stock
Why It's Time to Load Up on Micron Stock
Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.
Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.
These efforts have helped the company reach a market cap of approximately $25.3 billion, putting it above the $10 billion threshold commonly used to classify large-cap stocks.
The stock is currently trading just 4.3% below its 52-week high of $132.60, reached in July. Strength has been particularly evident in recent months, with Incyte's shares gaining 22.5% over the past three months and outperforming the State Street SPDR S&P Biotech ETF (XBI), which advanced 11% over the same period.
The stock's performance remains solid over longer time frames, although it has trailed the broader biotech ETF. Over the past 52 weeks, Incyte's shares have climbed 49.8%, compared with a 66.4% increase for XBI. Similarly, INCY stock is up 28.5% year-to-date (YTD), while the ETF climbed 32.8%.
From a technical perspective, the recent strength is also reflected in Incyte's moving averages. Since June, the stock has continued to trade above both its 50-day moving average of $122.72 and its 200-day moving average of $105.88, pointing to sustained upward momentum.
Incyte's recent rally reflects improving fundamentals and a stronger biotech backdrop, with investor interest in drug-development pipelines and innovation gaining momentum. The company's growth outlook has strengthened alongside better performance across its commercial portfolio, providing another layer of support for the stock.
Its Q2 FY2026 net sales increased 40.5% year over year (YOY) to $1.5 billion, while sales excluding a $246 million one-time benefit from Opzelura, a topical skin-treatment drug, rose 17%. Jakafi grew 6.9% YOY to $816.7 million, and Incyte's hematology and oncology portfolio surged 69%. Looking ahead, management also raised FY2026 sales guidance to $5.13 billion-$5.26 billion.
Incyte is further expanding its portfolio to diversify beyond Jakafi ahead of the drug's expected patent expiry in 2028. Opzelura continues to gain traction, while Niktimvo, Monjuvi/Minjuvi and Zynyz, a skin-cancer treatment, are emerging as additional revenue streams.
For perspective, Incyte's rival Exelixis, Inc. (EXEL) has posted comparable gains, with EXEL stock surging 46.9% over the past 52 weeks and rising 32.7% YTD.
Against this backdrop, analyst sentiment toward INCY stock remains favorable. Among 28 analysts covering the name, INCY has an overall "Moderate Buy" rating, with an average price target of $128.84. This implies potential upside of 1.5% from current levels.
On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Incyte Stock: Is INCY Outperforming the Healthcare Sector? Barchart • 3mo ago INCY
Incyte Stock: Is INCY Outperforming the Healthcare Sector?
Incyte Stock: Is Wall Street Bullish or Bearish? Barchart • 1mo ago INCY XLV
Incyte Stock: Is Wall Street Bullish or Bearish?
What to Expect From Incyte's Q2 2026 Earnings Report Barchart • 2mo ago INCY
What to Expect From Incyte's Q2 2026 Earnings Report
Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue? Zacks • 1mo ago INCY ^GSPC
Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue?
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold? Zacks • 16d ago INCY ^GSPC
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
Earnings Preview: What To Expect From Incyte's Report Barchart • 8mo ago INCY
Earnings Preview: What To Expect From Incyte's Report
Incyte (INCY): 3 Reasons We Love This Stock StockStory • 16d ago INCY ^GSPC
Incyte (INCY): 3 Reasons We Love This Stock
Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales Insider Monkey • 7mo ago INCY
Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales
RBC Capital Lifts PT on Incyte Corporation (INCY) to $95 From $92 Insider Monkey • 5mo ago INCY
RBC Capital Lifts PT on Incyte Corporation (INCY) to $95 From $92
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised Zacks • 2mo ago LLY NVS
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
